Prosecution Insights
Last updated: November 20, 2026

Hoi Yan Nmn Lee, USPTO Patent Examiner

Listed by the USPTO as LEE, HOI YAN NMN

Tech Center 1600 • Art Units: 1623 1693

This examiner grants 38% of resolved cases

Analysis

LEE, HOI YAN NMN handles cases in Tech Center 1600 and Art Unit 1623. The profile covers 91 resolved cases, with an allowance rate of 38.5% and a median of 1273 days to allowance. Interview lift is 74.9%, the most prominent feature of this record, and it supports treating examiner interviews as a central prosecution tool.

The leading companies are President and Fellows of Harvard College, The Brigham and Women's Hospital Inc., and CJ CheilJedang Corporation. Ipsilon USA - NLO, Leason Ellis LLP, and OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P. are the listed firms. Applicants may benefit from combining detailed written responses with well-prepared interviews.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

38.5%
Allow Rate
-21.5% vs TC avg
165
Total Applications
+74.9%
Interview Lift
1273
Avg Prosecution Days
Based on 91 resolved cases, 2023–2026

Rejection Statute Breakdown

3.0%
§101 Eligibility
16.1%
§102 Novelty
42.3%
§103 Obviousness
17.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17925180 OLEOGEL AND OLEOPASTE COMPOSITIONS AND USES THEREOF Non-Final OA The Brigham and Women's Hospital, Inc.
17297586 D-PSICOSE CRYSTAL AND PREPARATION METHOD THEREFOR Non-Final OA CJ CHEILJEDANG CORPORATION
18716928 FUNCTIONALIZED CYCLODEXTRIN MONOMER AND POLYMER FOR WATER REMEDIATION Non-Final OA Cornell University
17621987 LIQUID PHASE SEPARATION OF 2G SUGARS BY ADSORPTION ON A FAU ZEOLITE HAVING A SI/AL ATOMIC RATIO GREATER THAN 1.5 Final Rejection IFP Energies nouvelles
18788461 COMPOSITIONS AND METHODS FOR CANCER AND TUMOR TREATMENT Non-Final OA Washington University
18045744 COMPOSITIONS AND METHODS FOR PREDICTING THERAPEUTIC OUTCOME Non-Final OA Washington University
18695914 DERIVATIVES FROM 2,5,6-TRIMETHYLCYCLOHEX-2-EN-1-OL AS AROMA INGREDIENTS Non-Final OA BASF SE
17927616 METHOD OF PRODUCING ALIPHATIC GLYCOSIDE COMPOUND OR SUGAR FATTY ACID ESTER COMPOUND Final Rejection TOHOKU UNIVERSITY
18334457 LIQUID COMPOSITION Final Rejection Shin-Etsu Chemical Co., Ltd.
17606441 STABILIZATION AND PRESERVATION OF IN VITRO TRANSCRIPTION REACTIONS Final Rejection President and Fellows of Harvard College
17283728 ENZYMATIC RNA SYNTHESIS Non-Final OA President and Fellows of Harvard College
17995264 PREPARATION FOR USE AS VASORELAXANT Non-Final OA Evonik Operations GmbH
19262831 AMORPHOUS FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR Non-Final OA EffePharm (Shanghai) Co., Ltd.
18237624 NASAL SPRAY USING PENTOSAN POLYSULFATE AND MUCOPOLYSACCHARIDE POLYSULFATE FOR COVID-19 PREVENTION AND TREATMENT Final Rejection Rensselaer Polytechnic Institute
17998437 INORGANIC POROUS SUBSTRATE, INORGANIC POROUS SUPPORT, AND NUCLEIC ACID PRODUCTION METHOD Non-Final OA SUMITOMO CHEMICAL COMPANY, LIMITED
18714811 SUBSTRATES FOR IMAGING GLUCOCEREBROSIDASE ACTIVITY Non-Final OA SIMON FRASER UNIVERSITY
18568162 COMPOSITIONS FOR TREATMENT OF PSORIASIS Final Rejection THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
18577948 MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS Non-Final OA ALNYLAM PHARMACEUTICALS, INC.
18724813 MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF Non-Final OA SIGILON THERAPEUTICS, INC.
18048407 CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF Final Rejection Gritstone bio, Inc.
17298283 USE OF GUAR DERIVATIVES FOR MICROORGANISMS GROWTH Non-Final OA RHODIA OPERATIONS

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Hoi Yan Nmn Lee's allowance rate?

38.5% of resolved applications examined by Hoi Yan Nmn Lee were allowed (91 resolved cases), compared with 51.0% across Art Unit 1623 over the last five years.

Does an interview help with examiner Hoi Yan Nmn Lee?

This examiner's interview lift is +74.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Hoi Yan Nmn Lee take to allow a patent?

Applications allowed by Hoi Yan Nmn Lee took 1,273 days on average from filing to allowance.

Which art unit does examiner Hoi Yan Nmn Lee work in?

Hoi Yan Nmn Lee examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month